Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C33H52O4 |
| Molecular Weight | 512.7636 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 11 / 11 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12C[C@@]3([H])[C@]4([H])CC=C5C[C@H](CC[C@]5(C)[C@@]4([H])CC[C@]3(C)[C@@]1([H])[C@H](C)[C@@]6(CC[C@@H](C)CO6)O2)OC(=O)CCCCC
InChI
InChIKey=VMOZFSWFUBLCNN-AAPULDEBSA-N
InChI=1S/C33H52O4/c1-6-7-8-9-29(34)36-24-13-15-31(4)23(18-24)10-11-25-26(31)14-16-32(5)27(25)19-28-30(32)22(3)33(37-28)17-12-21(2)20-35-33/h10,21-22,24-28,30H,6-9,11-20H2,1-5H3/t21-,22+,24+,25-,26+,27+,28+,30+,31+,32+,33-/m1/s1
Caprospinol, also known as SP-233, a spirostenol derivative, protects neuronal cells against β-Amyloid (Abeta(1-42)) protein toxicity by binding to and inactivating this peptide. It was shown, that caprospinol crossed the blood-brain barrier, accumulated in the brain, and restored cognitive impairment in a pharmacological rat model of Alzheimer's disease. It was suggested, that the drug could be considered as a promising drug for Alzheimer's disease treatment.
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
16394575
Created by
admin on Sat Dec 16 09:38:55 GMT 2023 , Edited by admin on Sat Dec 16 09:38:55 GMT 2023
|
PRIMARY | |||
|
DB05263
Created by
admin on Sat Dec 16 09:38:55 GMT 2023 , Edited by admin on Sat Dec 16 09:38:55 GMT 2023
|
PRIMARY | |||
|
9BU4T267E4
Created by
admin on Sat Dec 16 09:38:55 GMT 2023 , Edited by admin on Sat Dec 16 09:38:55 GMT 2023
|
PRIMARY | |||
|
4952-56-1
Created by
admin on Sat Dec 16 09:38:55 GMT 2023 , Edited by admin on Sat Dec 16 09:38:55 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD
